Convert Pharmaceuticals develops tumor-microenvironment modulated prodrugs with a focus on hypoxia-activated cytotoxins. Its lead candidate, CP-506, is a hypoxia-activated cytotoxin designed by Prof. A. Patterson and Prof. J. Smaill from the University of Auckland, New Zealand. The company says CP-506 improves activity, specificity and safety relative to older hypoxia-activated prodrugs. Convert was co-founded by Droia, Prof. Dr. Philippe Lambin, Paul Tulcinsky and Nicolas Geûens and is based in Liège, Belgium. The newly raised funds will be used to prepare and conduct initial clinical studies of the lead drug. The financing comprises both equity and non-dilutive support.

Total raised

$17M

Funding rounds

2

Latest round

Equity

Latest activity

Feb 2018